ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
12 May 2020 09:23

EM Strategy and Chartbook: Remain Overweight EM Vs. EAFE

China (MSCI China, Shanghai Comp., Shenzhen A Share) continues to offer many attractive setups and is a major focus in today’s EM Strategy report....

Logo
306 Views
Share
26 Apr 2020 20:49

Tigermed IPO Initiation: Trade-Offs

Hangzhou Tigermed Consulting (300347 CH) is a global contract research organisation (CRO). Tigermed is the largest clinical CRO in China with a...

Logo
410 Views
Share
14 Apr 2020 17:24

Shorts Increase on Alibaba, AIA, CNOOC; Decrease on Ping An, CCB, Meituan

We take a look at the latest SFC data released today evening on short position reporting in Hong Kong for the week ended 3 April 2020.Total short...

Logo
374 Views
Share
13 Apr 2020 10:17

HK Connect Weekly: Chinese Were Buying China Feihe, Meituan

In our weekly HK Connect Flow series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed...

Logo
265 Views
Share
03 Apr 2020 17:23

Shorts Higher on Consumer Discretionary Stocks

We take a look at the latest SFC data released today evening on short position reporting in Hong Kong for the week ended 27 March 2020.Total short...

Logo
320 Views
Share
x